Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — FY2022 Earnings Presentation
8 slides from Sanara Medtech's earnings presentation, Mar 20, 2023
Slide 1: Q4 and Full-Year 2022 Earnings and Business Update Call
Q4 and Full-Year 2022 Earnings and Business Update Call
Slide 2: Disclaimers
“ Sanara axe |= MedTech Disclaimers ‘This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or nancial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara," “we,” ‘our’ of ‘us
Slide 3: Commentary on Q4 and Full-Year 2022
Sanara MedTech Commentary on Q4 and Full-Year 2022 + Financial Update * Highest net revenue year ($45.8 million) and quarter ($15.3 million) in the Company's history for the business as well as for the historical business before taking into account the $6.0 million in sales resulting from the Scendi
Slide 4: Product Sales
Sanara MedTech Product Sales Sales Overview + 39 field sales representatives as of December 31, 2022 + CellerateRX® Surgical sold in over 700 hospitals/ASCs across 29 states’) in the TTM € + CellerateRX® Surgical approved to be sold in more than 1,700 hospitals/ASCs as of December 31, 2022 + Total e
Slide 5: A Comprehensive Solution for Wound and Skin Care
Sanara MedTech A Comprehensive Solution for Wound and Skin Care Sanara MedTech’s Goals: + Bring a proven efficacious wound and skin care solution to patients in the lowest cost setting + Provide a comprehensive wound care solution that lowers costs through: 1. Early diagnosis 2. Decreased hospitaliz
Slide 6: 2022 Financial Highlights
Sanara MedTech 2022 Financial Highlights Overview + Revenue + For the year, Sanara generated net revenues of $45.8 million compared to net revenues of $24.1 million for the year ended December 31, 2021, representing a 90% increase from the prior year period. + 2022 net revenues included $6.0 million
Slide 7: Financial Highlights (Continued)
202 Sanara MedTech 2 Financial Highlights (Continued) Overview (Continued) + Other Expense Other expense for the year ended December 31, 2022 was $1.7 million compared to $0.6 million for the year ended December 31, 2021 Higher other expense in 2022 was primarily due to a $1.0 million loss recognize
Slide 8: Questions
Questions